The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complicationsNúria Mercadé‐Besora, Martí Català, Anneli Uusküla et al.|Heart|2024Cited by 50
Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular OutcomesRohan Khera, Patrick B. Ryan, Arya Aminorroaya et al.|Journal of the American College of Cardiology|2024Cited by 33
Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DMRohan Khera, Marc A. Suchard, Lovedeep Singh Dhingra et al.|BMJ Medicine|2023Cited by 27
Supporting Pharmacovigilance Signal Validation and Prioritization with Analyses of Routinely Collected Health Data: Lessons Learned from an EHDEN Network StudyOskar Gauffin, G. Niklas Norén, Judith S. Brand et al.|Drug Safety|2023Cited by 19
Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort StudyDaniel R. Morales, Marc A. Suchard, Fan Bu et al.|Diabetes Care|2025Cited by 14